Figure 5.
V56B2 retains full anti-TNFα and anti-IL-23 activity. (A) V56B2 and the trypsin-liberated V565 monomer arm were tested alongside the V565 parent in the biotinylated adalimumab competition ELISA. Biotinylated adalimumab in the absence of Vorabody was added as a control (B) V56B2 and the trypsin-liberated V900 monomer arm were also tested alongside the V900 parent in the IL-23/IL-23R ELISA. IL-23 in the absence of Vorabody was added as an assay control. Error bars = +/− SD. N = 3.